On the stock market since 2009, it operates in the world of health and science. It has 2,638 employees. Now — the numbers.
This is an established company with proven profits.
An average decline of 18% a year over the last 4 years — the most striking risk in this picture.
The gap is $3.7B. In times of high interest rates, a gap like that can squeeze a company.
The stock trades 41% below its peak. The market has trimmed its expectations for the company.
The net profit margin is 26% — still a thick cushion, though costs have been eating into it lately.
The average analyst price target is $38.30 — 32% above today’s price.
Over the last 3 years, sales fell about 36% a year on average. Profit is holding up, but a shrinking business is a risk worth watching.
Since the drop from its peak, buyer appetite hasn’t come back.
On our five-subject report card, GMAB sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: GMAB is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s whether the price paid for the stock is too high.